K
KINIKSA PHARMACEUTICALS LTD
NASDAQ: KNSA (Kiniksa Pharmaceuticals Interna)
Kemas kini terakhir: 2 hari lalu, 6:12PM77.91
-2.56 (-3.18%)
| Penutupan Terdahulu | 80.47 |
| Jumlah Dagangan | 429,616 |
| Harga / Pendapatan (P/E Ke hadapan) | 62.11 |
| Harga / Jualan (P/S) | 7.73 |
| Harga / Buku (P/B) | 9.46 |
| Julat 52 Minggu |
| Margin Keuntungan | -3.52% |
| Margin Operasi (TTM) | 9.63% |
| EPS Cair (TTM) | -0.240 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 72.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.17% |
| Nisbah Semasa (MRQ) | 3.66 |
| Aliran Tunai Operasi (OCF TTM) | 44.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 25.15 M |
| Pulangan Atas Aset (ROA TTM) | -1.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | Kiniksa Pharmaceuticals Interna | Bercampur | Menaik |
AISkor Stockmoo
0.0
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.80% |
| % Dimiliki oleh Institusi | 97.31% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |